Monetize the near-term pipeline catalysts: ELEVATE-45-201 Cohort 1 data (Oct 2026) is the next binary event; positive functional data could re-rate the stock. Cash runway into Q3 2027 removes near-term financing risk. No financial guidance was provided, so focus on clinical execution.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 5 $7.06entry
- T+1 · 3mo ago −2.69%α −2.53% · $6.87
- T+5 · 3mo ago +8.64%α +8.29% · $7.67
- T+20 · 3mo ago +3.40%α +4.00% · $7.30
- T+60 · 19d ago −37.68%α −37.62% · $4.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Entrada Therapeutics reported Q2 2026 results with collaboration revenue of $0.9M as the Vertex program winds down, and a GAAP net loss per share of -$1.01, beating the $-1.16 consensus by 12.9%. The company reiterated pipeline progress across its DMD franchise, with key data readouts for ELEVATE-45-201 Cohort 1 in October 2026 and ELEVATE-44-201 open-label data by year-end 2026. Cash of $223M provides runway into Q3 2027, but the significant year-over-year drop in collaboration revenue and ongoing operating losses keep the financial profile stable but unimproved.
Key Financial Metrics
Key Facts
- Q2 2026 GAAP EPS of -$1.01 vs consensus of -$1.16 (12.9% beat)
- Collaboration revenue declined to $0.9M from $2.0M in Q2 2025 (-54%) due to Vertex program wind-down
- Net loss was $42.8M vs $43.1M in the prior-year quarter, essentially flat
- Cash, cash equivalents, and marketable securities were $223.0M as of June 30, 2026, down from $295.7M at year-end 2025
- ELEVATE-44-201 Cohort 2 enrollment complete with data expected Q1 2027; Cohort 1 open-label data expected by year-end 2026
- ELEVATE-45-201 Cohort 1 data expected in October 2026; DMC cleared dose escalation to 10 mg/kg
- Vertex on track to report VX-670 Phase 1/2 data in H2 2026
Financial Impact
No material change in quarterly burn rate; revenue decline is expected as Vertex collaboration activities have largely completed. EPS beat is notable but driven by small absolute share count and low expectations for a pre-revenue biotech.
Risk Factors
- Revenue will continue to decline to near-zero as Vertex collaboration winds down, leaving the company without recurring revenue
- Clinical trial risk: Duchenne exon-skipping programs face high regulatory and efficacy hurdles
- Cash burn of ~$36M per quarter implies potential need for financing before mid-2027 if milestones are delayed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001689375-26-000052 |
| Document: trda-20260805.htm | 0001689375-26-000052 |
| Document: 0001689375-26-000052-index-headers.html | 0001689375-26-000052 |
| Document: 0001689375-26-000052-index.html | 0001689375-26-000052 |
| Document: 0001689375-26-000052.txt | 0001689375-26-000052 |
| 8-K Data (Synthetic) | 0001689375-26-000052 |
Track record
21 reports on TRDA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +58.22% at T+20 after the May 4, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
- Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
- Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers